Autologous transplants (using the patient’s own cells) are typically done for myeloma or lymphoma. This presentation reviews the potential complications that may arise from this procedure and provides numerous recommendations for how they can be managed or avoided.

Presenters: Mohamed Hegazi MD, UofL Brown Cancer Center Gerhard Hildebrandt MD, University of Kentucky Blood and Marrow Transplantation and Cellular Therapy Program Navneet Majhail MD, MS, FASTCT, Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial

Patients who have had a stem cell transplant have a higher risk of developing a second cancer than the general population. The risk of developing a second cancers increases over time. Life-long surveillance and testing is important to catch any second cancer early, when treatment is most effective.

CAR T-cell therapy is a new treatment option for patients with acute lymphoblastic leukemia, some lymphomas, and multiple myeloma that have not responded to prior therapies. This presentation describes how CAR T-cell therapy works, its risks and side effects, and how these may be effectively managed.